Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

Similar articles for PubMed (Select 21233426)

1.

The inverse benefit law: how drug marketing undermines patient safety and public health.

Brody H, Light DW.

Am J Public Health. 2011 Mar;101(3):399-404. doi: 10.2105/AJPH.2010.199844. Epub 2011 Jan 13.

2.

Drug policy: making effective drugs available without bankrupting the healthcare system.

Laupacis A, Anderson G, O'Brien B.

Healthc Pap. 2002;3(1):12-30. Review.

PMID:
12811107
3.

Reform of drug regulation--beyond an independent drug-safety board.

Ray WA, Stein CM.

N Engl J Med. 2006 Jan 12;354(2):194-201. No abstract available.

PMID:
16407517
4.

Preventing postmarketing changes in recommended doses and marketing withdrawals.

Peck C.

Ernst Schering Res Found Workshop. 2007;(59):209-16. Review.

PMID:
17117726
5.

Guidelines, editors, pharma and the biological paradigm shift.

Singh AR, Singh SA.

Mens Sana Monogr. 2007 Jan;5(1):27-30. doi: 10.4103/0973-1229.32176.

6.

Bad medicine: prescription drugs, preemption, and the potential for a no-fault fix.

Smirniotopoulos A.

Rev Law Soc Change. 2012;35(4):793-862.

PMID:
22363960
7.

Drug withdrawals from the Canadian market for safety reasons, 1963-2004.

Lexchin J.

CMAJ. 2005 Mar 15;172(6):765-7. No abstract available.

9.

Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.

Noah BA, Brushwood DB.

J Health Law. 2000 Summer;33(3):383-454.

PMID:
11184355
10.

Adverse event detection in drug development: recommendations and obligations beyond phase 3.

Berlin JA, Glasser SC, Ellenberg SS.

Am J Public Health. 2008 Aug;98(8):1366-71. doi: 10.2105/AJPH.2007.124537. Epub 2008 Jun 12.

11.

Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends.

Issa AM, Phillips KA, Van Bebber S, Nidamarthy HG, Lasser KE, Haas JS, Alldredge BK, Wachter RM, Bates DW.

Curr Drug Saf. 2007 Sep;2(3):177-85. Review.

PMID:
18690965
12.
13.

Five un-easy pieces of pharmaceutical policy reform.

Rodwin MA.

J Law Med Ethics. 2013 Fall;41(3):581-9. doi: 10.1111/jlme.12067.

PMID:
24088148
14.

National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse.

Butler SF, Budman SH, Licari A, Cassidy TA, Lioy K, Dickinson J, Brownstein JS, Benneyan JC, Green TC, Katz N.

Pharmacoepidemiol Drug Saf. 2008 Dec;17(12):1142-54. doi: 10.1002/pds.1659.

PMID:
18932173
15.
16.

The drugs industry: a bad product well marketed.

Abbasi K.

J R Soc Med. 2012 Jul;105(7):275. doi: 10.1258/jrsm.2012.12k048. No abstract available.

17.

[The role of drug registries in the post-marketing surveillance].

Traversa G, Sagliocca L, Magrini N, Venegoni M.

Recenti Prog Med. 2013 Jun;104(6):225-8. doi: 10.1701/1295.14321. Italian.

PMID:
23801224
19.

Pharmaceuticals and the health of the public: use, safety, cost, access, ethics, and quality.

Zito JM.

Med Care. 2012 Nov;50(11):907-9. doi: 10.1097/MLR.0b013e3182733b57. No abstract available.

PMID:
23047777
20.

Pharmacogenetics: policy needs for personal prescribing.

Melzer D, Raven A, Ling T, Detmer D, Zimmern R.

J Health Serv Res Policy. 2005 Jan;10(1):40-4.

PMID:
15667703
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk